BioSpace News Archive

Following the release of details from a surprise billing agreement between Senate Health, Education, Labor and Pensions Committee Chairman Lamar Alexander and House Energy and Commerce Committee Chairman Frank Pallone Jr. and Ranking Member Greg Walden, the American College of Emergency Physicians issued the following statement

CStone Pharmaceuticals updated results from the CS1001-201 trial in a poster presentation at the 2019 American Society of Hematology Annual Meeting.

Aptose Biosciences Inc. announced the presentation of preclinical data for its first-in-class, FLT3/BTK inhibitor CG-806 at the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, FL.

The first use of serum proteomics data to identify early indicators of response to treatment in a rare, hyperinflammatory, lymphoproliferative disorder (Idiopathic Multicentric Castleman disease) was presented at the 61st Annual Meeting of the American Society of Hematology.

Kite, a Gilead Company (Nasdaq: GILD), today announced primary results from ZUMA-2, a global, multicenter, single-arm, open-label Phase 2 study of KTE-X19, an investigational CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Castle Connolly Private Health Partners, LLC (“CCPHP”), a leading membership-based (or “concierge”) practice conversion and support company, is pleased to announce a collaboration with Dr. Woodson C. Merrell to establish a concierge medicine program at his practice.

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced updated results from a Phase 1/2 dose expansion study of flotetuzumab, an investigational, bispecific CD123 x CD3 DART® molecule in patients with primary induction failure and early relapsed acute myeloid leukemia (AML).

ImmunoGen, Inc., (Nasdaq: IMGN) a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that new safety and efficacy findings from the dose escalation and expansion of the first-in-human trial of IMGN632 in patients with relapsed/refractory acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN) were presented in an oral session at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, Florida

Technavio has announced its latest market research report titled global companion diagnostics market 2019-2023.

Enviva applauds a new report, The Future of Bioenergy, published December 5, 2019 in the Global Change Biology journal and authored by Walter Reid and Mariam Ali of The David and Lucile Packard Foundation and Christopher Field of the Stanford Woods Institute for the Environment.